Key Developments: Myrexis Inc (MYRX.PK)
0.08USD
24 May 2013
$0.00 (+7.14%)
$0.07
$0.07
$0.08
$0.07
71,400
212,656
$3.02
$0.06
Latest Key Developments (Source: Significant Developments)
Myrexis Inc Announces Appointment Of CFO-Form 8-K
Myrexis Inc reported in its Form 8-K that effective March 1, 2013, Jonathan M. Couchman was appointed Chief Financial Officer (CFO) of the Company. Mr. Couchman, currently the President and Chief Executive Officer (CEO) of the Company, also serves as Chairman of the Board, President, Chief Executive Officer (CFO) and Chief Financial Officer (CEO) of Xstelos Holdings, Inc., and has served in such capacity since January 23, 2012. Full Article
Myrexis Inc Announces Resignation Of David W. Gryska-Form 8-K
Myrexis Inc reported in its Form 8-K that on December 21, 2012, David W. Gryska informed Myrexis of his resignation as Acting President and Chief Executive Officer (CEO), Chief Operating Officer and member of the Board of Directors, effective December 24, 2012. Full Article
Myrexis Inc Announces Board Approval of Plan of Complete Liquidation and Dissolution
Myrexis Inc announced that its Board of Directors has determined, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets. In connection with the dissolution and liquidation the Company intends to distribute to its shareholders all available cash, except such cash as is required for paying or making reasonable provision for known and potential liabilities and other obligations of the Company. Full Article
EpiCept Corp Receives Notice of Termination of License and Collaboration Agreement with Myrexis, Inc
EpiCept Corp (EpiCept) announced that on September 5, 2012, it has received notice of termination, effective as of August 28, 2012, of its License and Collaboration Agreement with Myrexis, Inc (Myrexis). Among the compounds that had been licensed to Myrexis under the terminated agreement was EpiCept's anti-cancer drug candidate, Azixa. Azixa is a vascular disruption agent discovered by EpiCept that has demonstrated anti-cancer activity. Azixa has received orphan drug status in the United States (US) for the treatment of glioblastoma multiforme (GBM). In February 2012, Myrexis suspended development activities of all its preclinical and clinical programs in oncology and autoimmune diseases, and in May 2012 stated that it was focused on the identification, evaluation and acquisition of appropriate commercial-stage assets. Accordingly, Myrexis has elected to terminate its efforts to develop and commercialize any product, including Azixa, on any main market as such products and markets are defined in the License and Collaboration agreement dated November 19, 2003. As a result of the termination of the agreement, all rights and licenses granted under the agreement by EpiCept to Myrexis have terminated and reverted to EpiCept. Azixa was the subject of a two-arm Phase 2b trial in patients newly diagnosed with GBM initiated in December 2010, but not completed by Myrexis following its decision to suspend the development in September 2011. Full Article
Myrexis Inc Announces Death Of Chief Executive Officer Richard B. Brewer
Myrexis Inc announced that Richard B. Brewer, 61, its Chief Executive Officer and Board member, has died after a long battle with multiple myeloma, a type of blood cancer. Full Article
Myrexis Inc Announces Management Change-Form 8-K
Myrexis Inc reported in its Form 8-K that On May 11, 2012, Myrexis, Inc. announced a new executive management team, appointing Richard B. Brewer as President and Chief Executive Officer (CEO) and as a member of the Board of Directors and David W. Gryska as Chief Operating Officer and as a member of the Board of Directors. On May 7, 2012, Robert J. Lollini agreed to resign as the President and Chief Executive Officer of Myrexis, effective May 11, 2012. Mr. Lollini will continue as a member of Myrexis’ Board of Directors for a transitional period through November 15, 2012, at which time he has agreed to resign as a director. Mr. Lollini will receive no additional compensation for his continued service as a director. Full Article
Myrexis Inc Appoints Robert Lollini As CEO
Myrexis Inc announced that its Board of Directors has appointed current interim President and Chief Executive Officer (CEO) and Chief Financial Officer (CFO) Robert Lollini as its CEO, effective immediately. Mr. Lollini was also appointed as a member of the Board. Full Article
Myrexis Inc Announces Executive Management Changes
Myrexis, Inc. announced that Adrian N. Hobden, Ph.D. has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective July 21, 2011. The Board of Directors has appointed Robert J. Lollini, the Company's Chief Financial Officer, as interim President and Chief Executive Officer. Mr. Lollini will also continue has duties as Chief Financial Officer. The Board plans to initiate a search for a new CEO, looking at both internal and external candidates. In addition, Dr. Hobden has agreed to serve as a consultant to the Company for three months to assist in the transition. Full Article
Myrexis, Inc. Reports Azixa Phase 2 Study Results
Myrexis, Inc. announced Phase 2 clinical study results from its product candidate Azixa (verubulin). The Phase 2 results are from the Company's open-label Azixa monotherapy study in patients with recurrent glioblastoma multiforme (GBM) who had failed prior standard of care chemotherapy, but who are naive to Avastin (bevacizumab). There were 31 patients with recurrent GBM enrolled in this arm of the Phase 2 Azixa monotherapy study who had failed temozolomide and were naive to treatment with Avastin. 2 patients (6.5%) achieved partial response as assessed by Macdonald criteria. Another patient (3.2%) with 2 tumor lesions at baseline responded with no detectable disease after cycle 13 of Azixa treatment and continues to receive Azixa. A further 5 patients (16.1%) achieved stable disease. The median duration of stable disease was 4 months and the median duration of partial response was six months. The median progression-free duration was 1.8 months (range 0.04-13.1) and the median overall survival was 9.9 months (range 1.1-17.2). The most common adverse events were fatigue (26%), nausea (10%), and constipation (10%). The Company also presented a second poster highlighting preclinical findings from its potential cancer metabolism inhibitor (CMI) program. MPC-9528, which is currently in IND-enabling studies and MPI-0487316, representing a structurally distinct lead class of CMI compounds, both demonstrated flexible dosing and dramatic tumor regression across multiple tumor types. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
